4D Molecular Therapeutics (NASDAQ:FDMT) Sees Large Volume Increase – Should You Buy?

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) saw an uptick in trading volume on Monday. Approximately 733,855 shares changed hands during mid-day trading, a decline of 12% from the previous session’s volume of 837,695 shares. The stock last traded at $14.1280 and had previously closed at $14.47.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Chardan Capital upgraded 4D Molecular Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. HC Wainwright restated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. Cantor Fitzgerald upgraded 4D Molecular Therapeutics from a “neutral” rating to an “overweight” rating and set a $20.00 price objective on the stock in a research note on Monday, September 14th. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $32.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $28.56.

4D Molecular Therapeutics Price Performance

The stock has a fifty day moving average of $13.17 and a two-hundred day moving average of $11.08. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $802.31 million, a price-to-earnings ratio of -5.53 and a beta of 2.74.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. The company had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.62 million. As a group, equities research analysts forecast that 4D Molecular Therapeutics, Inc. will post -4.07 earnings per share for the current year.

Insider Buying and Selling

In other news, insider David Kirn sold 58,333 shares of the business’s stock in a transaction on Monday, September 14th. The stock was sold at an average price of $13.90, for a total transaction of $810,828.70. Following the completion of the transaction, the insider owned 767,486 shares of the company’s stock, valued at approximately $10,668,055.40. The trade was a 7.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last 90 days, insiders have sold 134,570 shares of company stock valued at $1,743,197. 7.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Hedge funds have recently made changes to their positions in the business. Jupiter Topco LLC purchased a new position in shares of 4D Molecular Therapeutics in the second quarter worth $76,466,000. BlackRock Inc. purchased a new stake in shares of 4D Molecular Therapeutics during the 2nd quarter valued at about $60,463,000. Trails Edge Capital Partners LP bought a new stake in shares of 4D Molecular Therapeutics during the 2nd quarter worth approximately $29,631,296. Bank of America Corp DE purchased a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter worth $14,905,000. Finally, Evergreen Quality Fund GP Ltd. purchased a new position in shares of 4D Molecular Therapeutics in the 4th quarter worth approximately $7,136,000. 99.27% of the stock is currently owned by institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company developing genetic medicines for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to engineer and select adeno-associated virus (AAV) vectors designed to deliver genetic payloads to specific tissues and support the development of potentially durable, one-time treatments.

Its research and development programs have focused primarily on ophthalmic and pulmonary diseases.